National Trends of Structural Heart Disease Interventions from 2016 to 2020 in the United States and the Associated Impact of COVID-19 Pandemic.
Journal
Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
22
11
2022
accepted:
25
11
2022
pubmed:
2
12
2022
medline:
1
2
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
The Coronavirus Disease-2019 (COVID-19) pandemic placed an enormous strain on the healthcare system. Data on the impact of COVID-19 on the utilization and outcomes of structural heart disease interventions in the United States are scarce. The National Inpatient Sample from 2016 to 2020 was queried to identify adult admissions for transcatheter aortic valve replacement (TAVR), left atrial appendage occlusion (LAAO), and transcatheter end-to-end repair (TEER). The primary outcome was temporal trends of procedure utilization rate per 100,000 admissions over quarters from 2016 to 2020. The secondary outcomes were adjusted rates of in-hospital mortality, major complications, and length of stay (LOS). Among 434,630 weighted admissions (TAVR: 305,550; LAAO: 89,300; TEER: 40,160), 95,010 admissions (22%) were during the COVID-19 era. There was a decline during the second quarter of 2020 followed by an increase to the pre pandemic levels (TAVR: 220 to 253, LAAO: 57 to 109, and TEER: 31 to 36 per 100,000 admissions, Ptrend<0.001). There were no differences in the mortality or major complication rates. Median LOS has decreased in TAVR (4 days-1 day) and in TEER (3 days-1 day) but remained stable in LAAO (1 day). This nationwide analysis showed that structural heart disease interventions decreased during the early waves of COVID-19 pandemic. There was a significant reduction in hospital LOS without differences in in-hospital mortality or complication rates during the pandemic. These data suggest that hospitals adapted to the unprecedent challenges during the pandemic to provide advanced cardiac care to patients.
Identifiants
pubmed: 36455795
pii: S0146-2806(22)00423-6
doi: 10.1016/j.cpcardiol.2022.101526
pmc: PMC9701641
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101526Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Eur Heart J Suppl. 2020 Dec 23;22(Suppl Pt t):P47-P52
pubmed: 33390871
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Am J Cardiol. 2022 Jun 15;173:149-151
pubmed: 35431051
Cardiovasc Revasc Med. 2020 Aug;21(8):1030-1033
pubmed: 32736981
G Ital Cardiol (Rome). 2020 Nov;21(11 Suppl 1):45S-47S
pubmed: 33295334
Neth Heart J. 2022 Nov;30(11):503-509
pubmed: 35648264
Cardiovasc Revasc Med. 2020 Aug;21(8):950-953
pubmed: 32473912
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Catheter Cardiovasc Interv. 2021 Apr 1;97(5):912-916
pubmed: 33197110
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
J Am Coll Cardiol. 2021 Dec 7;78(23):2326-2353
pubmed: 34711430
JACC Cardiovasc Interv. 2022 Mar 28;15(6):590-598
pubmed: 35331450
Struct Heart. 2021 Jan-Feb;5(1):97-98
pubmed: 35378851
Eur Heart J Case Rep. 2021 Oct 01;5(10):ytab397
pubmed: 34693199
Eur Heart J Case Rep. 2021 Jan 12;5(2):ytaa556
pubmed: 33598624
JAMA Netw Open. 2020 Sep 1;3(9):e2019801
pubmed: 32997121
Curr Cardiol Rep. 2022 Jun;24(6):679-687
pubmed: 35347567
Curr Probl Cardiol. 2022 Feb;47(2):100934
pubmed: 34384618
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):659-663
pubmed: 32251546
Eur Heart J Qual Care Clin Outcomes. 2021 May 3;7(3):247-256
pubmed: 33079204
Am J Cardiol. 2021 Apr 15;145:97-101
pubmed: 33454341
Circulation. 2018 Jul 31;138(5):483-493
pubmed: 29511000
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
Curr Atheroscler Rep. 2020 Jun 10;22(7):29
pubmed: 32524266